Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ventricular Tachycardia - Pipeline Review, H2 2016, provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape.
Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness of breath. Causes include cardiomyopathy, ischemic heart disease and heart failure. Risk factors include age, family history and medical history. Treatment includes antiarrhythmic medication.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ventricular Tachycardia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 3 respectively.Ventricular Tachycardia.
Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ventricular Tachycardia (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ventricular Tachycardia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ventricular Tachycardia (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ventricular Tachycardia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ventricular Tachycardia (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ventricular Tachycardia (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ventricular Tachycardia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Armetheon Inc
Audentes Therapeutics Inc
Gilead Sciences Inc
HUYA Bioscience International LLC
InCarda Therapeutics Inc
Milestone Pharmaceuticals Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ventricular Tachycardia Overview 6
Therapeutics Development 7
Pipeline Products for Ventricular Tachycardia - Overview 7
Ventricular Tachycardia - Therapeutics under Development by Companies 8
Ventricular Tachycardia - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Ventricular Tachycardia - Products under Development by Companies 11
Ventricular Tachycardia - Companies Involved in Therapeutics Development 12
Armetheon Inc 12
Audentes Therapeutics Inc 13
Gilead Sciences Inc 14
HUYA Bioscience International LLC 15
InCarda Therapeutics Inc 16
Milestone Pharmaceuticals Inc 17
Ventricular Tachycardia - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
aladorian sodium - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
AT-307 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
budiodarone - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
etripamil - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
flecainide acetate - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
GS-967 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
HBI-3000 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Ventricular Tachycardia - Dormant Projects 35
Ventricular Tachycardia - Discontinued Products 36
Ventricular Tachycardia - Product Development Milestones 37
Featured News & Press Releases 37
Aug 31, 2016: InCarda Therapeutics Initiates Enrollment of Phase 1 Clinical Trial of Inhaled Flecainide for the Treatment of Cardiac Arrhythmias 37
Jan 25, 2016: Milestone Pharmaceuticals Announces USAN Approval of Generic Name "Etripamil" for its Phase 2 Clinical Development Product for the Treatment of Paroxysmal Supraventricular Tachycardia 37
Jan 12, 2015: Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND 37
Nov 24, 2014: Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 38
Oct 28, 2013: Milestone Pharmaceuticals Initiates a Phase 1 Clinical Trial with MSP-2017 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41
List of Tables
Number of Products under Development for Ventricular Tachycardia, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Ventricular Tachycardia - Pipeline by Armetheon Inc, H2 2016 12
Ventricular Tachycardia - Pipeline by Audentes Therapeutics Inc, H2 2016 13
Ventricular Tachycardia - Pipeline by Gilead Sciences Inc, H2 2016 14
Ventricular Tachycardia - Pipeline by HUYA Bioscience International LLC, H2 2016 15
Ventricular Tachycardia - Pipeline by InCarda Therapeutics Inc, H2 2016 16
Ventricular Tachycardia - Pipeline by Milestone Pharmaceuticals Inc, H2 2016 17
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Stage and Target, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Ventricular Tachycardia - Dormant Projects, H2 2016 35
Ventricular Tachycardia - Discontinued Products, H2 2016 36
List of Figures
Number of Products under Development for Ventricular Tachycardia, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Assessment by Monotherapy Products, H2 2016 18
Number of Products by Targets, H2 2016 19
Number of Products by Stage and Targets, H2 2016 19
Number of Products by Mechanism of Actions, H2 2016 21
Number of Products by Stage and Mechanism of Actions, H2 2016 21
Number of Products by Routes of Administration, H2 2016 23
Number of Products by Stage and Routes of Administration, H2 2016 23
Number of Products by Molecule Types, H2 2016 25
Number of Products by Stage and Molecule Types, H2 2016 25
